Circle Pharma Raises $92.5M to Advance CID-165
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Circle Pharma, Inc. announced an oversubscribed $92.5 million Series E financing...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Circle Pharma, Inc. announced an oversubscribed $92.5 million Series E financing...
WATERTOWN, Mass., August 6, 2026 LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of...
